Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sukaina Virji
The European Medicines Agency's advisory committee, the CHMP, unusually issued three negative opinions at its recent monthly meeting. Which companies received an unexpected boon at the news?
The WHO has elected its first African director general, Dr Tedros Adhanom Ghebreyesus of Ethiopia. He begins his five-year term on July 1, succeeding Dr Margaret Chan of China who has held the top job for a decade.
The UK's anti-competition authority has accused Merck & Co of anti-competitive behavior in its UK pricing strategy for its infliximab product Remicade.
Aduro Biotech's scientists have a long association with Merck & Co's Keytruda, and things have come full circle as the small biotech's lead anticancer shows promise in combination with the high-profile checkpoint inhibitor.
Merck of Germany has developed a new genome editing tool that it believes improves on the popular, but IP battle-worn, CRISPR technology. How this will affect the existing IP landscape is as yet unknown.
Analysts' views on what the Humira formulation patent loss this week could mean for the launch timing of a biosimilar to AbbVie's main revenue driver vary.